Skip to main content
The AAPS Journal logoLink to The AAPS Journal
. 2006 May 12;8(2):E337. doi: 10.1007/BF02854904

Causes and consequences of methamphetamine and MDMA toxicity

Maria S Quinton 1, Bryan K Yamamoto 1,
PMCID: PMC3231568  PMID: 16796384

Abstract

Methamphetamine (METH) and its derivative 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) are 2 substituted amphetamines with very high abuse liability in the United States. These amphetamine-like stimulants have been associated with loss of multiple markers for dopaminergic and serotonergic terminals in the brain. Among other causes, oxidative stress, excitotoxicity and mitochondrial dysfunction appear to play a major role in the neurotoxicity produced by the substituted amphetamines. The present review will focus on these events and how they interact and converge to produce the monoaminergic depletions that are typically observed after METH or MDMA administration. In addition more recently identified consequences of METH or MDMA-induced oxidative stress, excitotoxicity, and mitochondrial dysfunction are described in relation to the classical markers of METH-induced damage to dopamine terminals.

Keywords: substituted amphetamines, excitotoxicity, oxidative stress, mitochondrial dysfunction, glutamate, blood-brain barrier

Full Text

The Full Text of this article is available as a PDF (340.1 KB).

References

  • 1.Hotchkiss AJ, Morgan ME, Gibb JW. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci. 1979;25:1373–1378. doi: 10.1016/0024-3205(79)90414-4. [DOI] [PubMed] [Google Scholar]
  • 2.Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980;181:151–160. doi: 10.1016/0006-8993(80)91265-2. [DOI] [PubMed] [Google Scholar]
  • 3.Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 1980;193:153–163. doi: 10.1016/0006-8993(80)90952-X. [DOI] [PubMed] [Google Scholar]
  • 4.Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 1994;17:203–209. doi: 10.1002/syn.890170310. [DOI] [PubMed] [Google Scholar]
  • 5.Raiteri M, Cerrito F, Cervoni AM, Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther. 1979;208:195–202. [PubMed] [Google Scholar]
  • 6.Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res. 1990;26:428–435. doi: 10.1002/jnr.490260405. [DOI] [PubMed] [Google Scholar]
  • 7.Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 1992;581:237–243. doi: 10.1016/0006-8993(92)90713-J. [DOI] [PubMed] [Google Scholar]
  • 8.Mark KA, Soghomonian JJ, Yamamoto BK. High-dose methamphetamine acutely activates the striatoningral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci. 2004;24:11449–11456. doi: 10.1523/JNEUROSCI.3597-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Yamamoto BK, Gudelsky G, Stephans SE. Progress in HPLC-HPCE. Utrecht, The Netherlands: VSP; 1998. Amphetamine neurotoxicity. Roles for dopamine, glutamate and oxidative stress; pp. 223–244. [Google Scholar]
  • 10.Rocher C, Gardier AM. Effects of repeated systemic administration of d-fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:422–428. doi: 10.1007/s002100000381. [DOI] [PubMed] [Google Scholar]
  • 11.Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther. 2003;99:45–53. doi: 10.1016/S0163-7258(03)00052-4. [DOI] [PubMed] [Google Scholar]
  • 12.Brown JM, Quinton MS, Yamamoto BK. Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J Neurochem. 2005;95:429–436. doi: 10.1111/j.1471-4159.2005.03379.x. [DOI] [PubMed] [Google Scholar]
  • 13.Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther. 1980;214:257–262. [PubMed] [Google Scholar]
  • 14.Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol. 1987;36:4095–4102. doi: 10.1016/0006-2952(87)90566-1. [DOI] [PubMed] [Google Scholar]
  • 15.Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse. 1998;30:433–445. doi: 10.1002/(SICI)1098-2396(199812)30:4<433::AID-SYN10>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  • 16.Seiden LS, Fischman MW, Schuster CR. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1976;1:215–219. doi: 10.1016/0376-8716(76)90030-2. [DOI] [PubMed] [Google Scholar]
  • 17.Finnegan KT, Ricaurte G, Seiden LS, Schuster CR. Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine. Psychopharmacology (Berl) 1982;77:43–52. doi: 10.1007/BF00436098. [DOI] [PubMed] [Google Scholar]
  • 18.Green AR, De Souza RJ, Williams JL, Murray TK, Cross AJ. The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole. Neuropharmacology. 1992;31:315–321. doi: 10.1016/0028-3908(92)90062-T. [DOI] [PubMed] [Google Scholar]
  • 19.Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 1989;486:73–78. doi: 10.1016/0006-8993(89)91279-1. [DOI] [PubMed] [Google Scholar]
  • 20.McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone uses: evidence from positron emission tomography studies with [11C]WIN-35, 428. J Neurosci. 1998;18:8417–8422. doi: 10.1523/JNEUROSCI.18-20-08417.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, de Souza EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther. 1987;242:911–916. [PubMed] [Google Scholar]
  • 22.O'Hearn E, Battaglia G, de Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988;8:2788–2803. doi: 10.1523/JNEUROSCI.08-08-02788.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, Langston JW. Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res. 1988;447:141–144. doi: 10.1016/0006-8993(88)90974-2. [DOI] [PubMed] [Google Scholar]
  • 24.Ricaurte GA, Forno LS, Wilson MA. (+/−)3,4-Methylene-dioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988;260:51–55. doi: 10.1001/jama.260.1.51. [DOI] [PubMed] [Google Scholar]
  • 25.Steele TD, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): pharmacology and toxicology in animals and humans. Addiction. 1994;89:539–551. doi: 10.1111/j.1360-0443.1994.tb03330.x. [DOI] [PubMed] [Google Scholar]
  • 26.McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/−)3,4-methylenedioxymethamphetamine (MDMA; “Ecstasy”): a controlled study in humans. Neuropsychopharmacology. 1994;10:129–138. doi: 10.1038/npp.1994.15. [DOI] [PubMed] [Google Scholar]
  • 27.Malberg JE, Sabol KE, Seiden LS. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther. 1996;278:258–267. [PubMed] [Google Scholar]
  • 28.Fleckenstein AE, Wilkins DG, Gibb JW, Hanson GR. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther. 1997;283:281–285. [PubMed] [Google Scholar]
  • 29.Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 1982;235:93–103. doi: 10.1016/0006-8993(82)90198-6. [DOI] [PubMed] [Google Scholar]
  • 30.Eisch AJ, Schmued LC, Marshall JF. Characterizing cortical neuron injury with fluoro-jade labeling after a neurotoxic regimen of methamphetamine. Synapse. 1998;30:329–333. doi: 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  • 31.O'Dell SJ, Marshall JF. Neurotoxic regimens of methamphetamine induce persistent expression of phospho-c-Jun in somatosensory cortex and substantia nigra. Synapse. 2005;55:137–147. doi: 10.1002/syn.20098. [DOI] [PubMed] [Google Scholar]
  • 32.O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf. 2005;4:433–442. doi: 10.1517/14740338.4.3.433. [DOI] [PubMed] [Google Scholar]
  • 33.Pu C, Fisher JE, Cappon GD, Vorhees CV. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res. 1994;649:217–224. doi: 10.1016/0006-8993(94)91067-7. [DOI] [PubMed] [Google Scholar]
  • 34.Miller DB, O'Callaghan JP. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther. 1994;270:752–760. [PubMed] [Google Scholar]
  • 35.Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther. 1987;241:338–345. [PubMed] [Google Scholar]
  • 36.Stone DM, Johnson M, Hanson GR, Gibb JW. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol. 1989;172:93–97. doi: 10.1016/0922-4106(89)90048-5. [DOI] [PubMed] [Google Scholar]
  • 37.Gibb JW, Johnson M, Hanson GR. Neurochemical basis of neurotoxicity. Neurotoxicology. 1990;11:317–321. [PubMed] [Google Scholar]
  • 38.Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology. 1986;25:559–561. doi: 10.1016/0028-3908(86)90184-X. [DOI] [PubMed] [Google Scholar]
  • 39.Gudelsky GA. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J Neural Transm. 1996;103:1397–1404. doi: 10.1007/BF01271253. [DOI] [PubMed] [Google Scholar]
  • 40.Colado MI, Green AR. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents “ecstasy”-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol. 1995;280:343–346. doi: 10.1016/0014-2999(95)00298-Y. [DOI] [PubMed] [Google Scholar]
  • 41.Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 2004;1016:90–95. doi: 10.1016/j.brainres.2004.04.072. [DOI] [PubMed] [Google Scholar]
  • 42.Stone DM, Johnson M, Hanson GR, Gibb JW. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther. 1988;247:79–87. [PubMed] [Google Scholar]
  • 43.Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther. 1985;233:539–544. [PubMed] [Google Scholar]
  • 44.Gudelsky GA, Nash JF. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem. 1996;66:243–249. doi: 10.1046/j.1471-4159.1996.66010243.x. [DOI] [PubMed] [Google Scholar]
  • 45.Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) Pharmacol Rev. 2003;55:463–508. doi: 10.1124/pr.55.3.3. [DOI] [PubMed] [Google Scholar]
  • 46.Marek GJ, Vosmer G, Seiden LS. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 1990;513:274–279. doi: 10.1016/0006-8993(90)90467-P. [DOI] [PubMed] [Google Scholar]
  • 47.Sprague JE, Everman SL, Nichols DE. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 1998;19:427–441. [PubMed] [Google Scholar]
  • 48.Breier JM, Bankson MG, Yamamoto BK. L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions. J Neurosci. 2006;26:290–299. doi: 10.1523/JNEUROSCI.3353-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Bai F, Jones DC, Lau SS, Monks TJ. Serotonergic neurotoxicity of 3,4-(+/−)-methylenedioxyamphetamine and 3,4-(+/−)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem Res Toxicol. 2001;14:863–870. doi: 10.1021/tx010011l. [DOI] [PubMed] [Google Scholar]
  • 50.Jones DC, Lau SS, Monks TJ. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J Pharmacol Exp Ther. 2004;311:298–306. doi: 10.1124/jpet.104.069260. [DOI] [PubMed] [Google Scholar]
  • 51.Jiang XR, Wrona MZ, Alguindigue SS, Dryhurst G. Reactions of the putative neurotoxin tryptamine-4,5-dione with L-cysteine and other thiols. Chem Res Toxicol. 2004;17:357–369. doi: 10.1021/tx020084k. [DOI] [PubMed] [Google Scholar]
  • 52.Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (‘ecstasy’) and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol. 1997;121:889–900. doi: 10.1038/sj.bjp.0701213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Shankaran M, Yamamoto BK, Gudelsky GA. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol. 1999;385:103–110. doi: 10.1016/S0014-2999(99)00728-1. [DOI] [PubMed] [Google Scholar]
  • 54.Shankaran M, Yamamoto BK, Gudelsky GA. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J Neurochem. 1999;72:2516–2522. doi: 10.1046/j.1471-4159.1999.0722516.x. [DOI] [PubMed] [Google Scholar]
  • 55.Giovanni A, Liang LP, Hastings TG, Zigmond MJ. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J Neurochem. 1995;64:1819–1825. doi: 10.1046/j.1471-4159.1995.64041819.x. [DOI] [PubMed] [Google Scholar]
  • 56.Iman SZ, Yazal J, Newport GD, et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann NY Acad Sci. 2001;939:366–380. doi: 10.1111/j.1749-6632.2001.tb03646.x. [DOI] [PubMed] [Google Scholar]
  • 57.Shankaran M, Yamamoto BK, Gudelsky GA. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse. 2001;40:55–64. doi: 10.1002/1098-2396(200104)40:1<55::AID-SYN1026>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  • 58.Sprague JE, Nichols DE. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther. 1995;273:667–673. [PubMed] [Google Scholar]
  • 59.Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther. 1998;287:107–114. [PubMed] [Google Scholar]
  • 60.Acikgoz O, Gonenc S, Kayatekin BM, et al. Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res. 1998;813:200–202. doi: 10.1016/S0006-8993(98)01020-8. [DOI] [PubMed] [Google Scholar]
  • 61.Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem. 2001;79:152–160. doi: 10.1046/j.1471-4159.2001.00549.x. [DOI] [PubMed] [Google Scholar]
  • 62.Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem. 1996;67:1770–1773. doi: 10.1046/j.1471-4159.1996.67041770.x. [DOI] [PubMed] [Google Scholar]
  • 63.Colado MI, Camarero J, Mechan AO, et al. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain. Br J Pharmacol. 2001;134:1711–1723. doi: 10.1038/sj.bjp.0704435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Darvesh AS, Yamamoto BK, Gudelsky GA. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain. J Pharmacol Exp Ther. 2005;312:694–701. doi: 10.1124/jpet.104.074849. [DOI] [PubMed] [Google Scholar]
  • 65.Kuhn DM, Sadidi M, Liu X. Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis. J Biol Chem. 2002;277:14336–14342. doi: 10.1074/jbc.M200290200. [DOI] [PubMed] [Google Scholar]
  • 66.Sattler R, Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity. J Mol Med. 2000;78:3–13. doi: 10.1007/s001090000077. [DOI] [PubMed] [Google Scholar]
  • 67.Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613–622. doi: 10.1056/NEJM199403033300907. [DOI] [PubMed] [Google Scholar]
  • 68.Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 1989;243:398–400. doi: 10.1126/science.2563176. [DOI] [PubMed] [Google Scholar]
  • 69.Finnegan KT, Taraska T. Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo. J Neurochem. 1996;66:1949–1958. doi: 10.1046/j.1471-4159.1996.66051949.x. [DOI] [PubMed] [Google Scholar]
  • 70.Albers DS, Sonsalla PK. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther. 1995;275:1104–1114. [PubMed] [Google Scholar]
  • 71.Battaglia G, Fornai F, Busceti CL, et al. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci. 2002;22:2135–2141. doi: 10.1523/JNEUROSCI.22-06-02135.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Burrows KB, Meshul CK. Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex. Synapse. 1997;27:133–144. doi: 10.1002/(SICI)1098-2396(199710)27:2<133::AID-SYN4>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 73.Mark KA, Eyerman DJ, Yamamoto BK. The Effects of Methamphetamine on the Vesicular Glutamate Transporter 1. Program No. 681. 18.2005 Abstract Viewer/Itinerary Planner. 2005; Available at: http://sfn.scholarone.com/itin2005/main.html? new_page_id=126&abstract_id=16249&p_num=681.18&is_tech=0. Accessed November 15, 2005.
  • 74.Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci. 1989;9:1579–1590. doi: 10.1523/JNEUROSCI.09-05-01579.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Minger SL, Geddes JW, Holtz ML, et al. Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia. Brain Res. 1998;810:181–199. doi: 10.1016/S0006-8993(98)00921-4. [DOI] [PubMed] [Google Scholar]
  • 76.Staszewski RD, Yamamoto BK. Methamphetamine-induced spectrin proteolysis in the rat striatum. J Neurochem. 2006;96:1267–1276. doi: 10.1111/j.1471-4159.2005.03618.x. [DOI] [PubMed] [Google Scholar]
  • 77.Schmidt HH, Hofmann H, Schindler U, Shutenko ZS, Cunningham DD, Feelisch M. No NO from NO synthase. Proc Natl Acad Sci USA. 1996;93:14492–14497. doi: 10.1073/pnas.93.25.14492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Kahlert S, Zundorf G, Reiser G. Glutamate-mediated influx of extracellular Ca2+ is coupled with reactive oxygen species generation in cultured hippocampal neurons but not in astrocytes. J Neurosci Res. 2005;79:262–271. doi: 10.1002/jnr.20322. [DOI] [PubMed] [Google Scholar]
  • 79.Chan P, Di Monte DA, Luo JJ, DeLanney LE, Irwin I, Langston JW. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J Neurochem. 1994;62:2484–2487. doi: 10.1046/j.1471-4159.1994.62062484.x. [DOI] [PubMed] [Google Scholar]
  • 80.Nixdorf WL, Burrows KB, Gudelsky GA, Yamamoto BK. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J Neurochem. 2001;77:647–654. doi: 10.1046/j.1471-4159.2001.00262.x. [DOI] [PubMed] [Google Scholar]
  • 81.Albers DS, Zeevalk GD, Sonsalla PK. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res. 1996;718:217–220. doi: 10.1016/0006-8993(96)00135-7. [DOI] [PubMed] [Google Scholar]
  • 82.Burrows KB, Nixdorf WL, Yamamoto BK. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J Pharmacol Exp Ther. 2000;292:853–860. [PubMed] [Google Scholar]
  • 83.Stephans SE, Whittingham TS, Douglas AJ, Lust WD, Yamamoto BK. Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum. J Neurochem. 1998;71:613–621. doi: 10.1046/j.1471-4159.1998.71020613.x. [DOI] [PubMed] [Google Scholar]
  • 84.Wan FJ, Lin HC, Kang BH, Tseng CJ, Tung CS. D-amphetamine-induced depletion of energy and dopamine in the rat striatum is attenuated by nicotinamide pretreatment. Brain Res Bull. 1999;50:167–171. doi: 10.1016/S0361-9230(99)00185-9. [DOI] [PubMed] [Google Scholar]
  • 85.Zeevalk GD, Derr-Yellin E, Nicklas WJ. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J Pharmacol Exp Ther. 1995;275:1124–1130. [PubMed] [Google Scholar]
  • 86.Darvesh AS, Shankaran M, Gudelsky GA. 3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J Pharmacol Exp Ther. 2002;301:138–144. doi: 10.1124/jpet.301.1.138. [DOI] [PubMed] [Google Scholar]
  • 87.Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol. 2000;398:11–18. doi: 10.1016/S0014-2999(00)00264-8. [DOI] [PubMed] [Google Scholar]
  • 88.Kushnareva YE, Wiley SE, Ward MW, Andreyev AY, Murphy AN. Excitotoxic injury to mitochondria isolated from cultured neurons. J Biol Chem. 2005;280:28894–28902. doi: 10.1074/jbc.M503090200. [DOI] [PubMed] [Google Scholar]
  • 89.Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem. 2000;74:2221–2223. doi: 10.1046/j.1471-4159.2000.0742221.x. [DOI] [PubMed] [Google Scholar]
  • 90.Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol. 2002;449:71–74. doi: 10.1016/S0014-2999(02)01985-4. [DOI] [PubMed] [Google Scholar]
  • 91.Eyerman DJ, Yamamoto BK. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther. 2005;312:160–169. doi: 10.1124/jpet.104.072264. [DOI] [PubMed] [Google Scholar]
  • 92.Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves antophagy and upregulation of dopamine synthesis. J Neurosci. 2002;22:8951–8960. doi: 10.1523/JNEUROSCI.22-20-08951.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Eyerman DJ, Yamamoto BK. A Rapid and Long-lasting Decrease in Vesicular Monoamine Transporter 2 Immunoreactivity in Striatal Synaptosomes After Methamphetamine. Program No. 981.17.2005. Abstract Viewer/Itinerary Planner 2005; Available at: http://sfn. scholarone.com/itin2005/main.html? new_page_id=126&abstract_id=17188&p_num=918.17&is_tech=0. Accessed April 27, 2006.
  • 94.Hatzipetros T, Yamamoto BK. Dopaminergic and GABAergic modulation of glutamate release from subthalamic nucleus efferents to the rat substantia nigra. Brain Res. 2006;1076:60–67. doi: 10.1016/j.brainres.2006.01.015. [DOI] [PubMed] [Google Scholar]
  • 95.Bustamante D, You ZB, Castel MN, et al. Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat. J Neurochem. 2002;83:645–654. doi: 10.1046/j.1471-4159.2002.01171.x. [DOI] [PubMed] [Google Scholar]
  • 96.Hatzipetros T, Yamamoto BK. Methamphetamine-induced Spectrin Proteolysis and Dopamine Depletions in the Substantia Nigra. Program No. 563.15.2004. Abstract Viewer/Itinerary Planner. 2004;Available at: http://sfn.scholarone.com/itin2004/main.html? new_page_id=126&abstract_id=10146&p_num=563.15&is_tech=0. Accessed April 27, 2006.
  • 97.Hatzipetros T, Yamamoto BK. The Effects of Haloperidol Treatment After Methamphetamine On the Neuronal Population of the Rat Substantia Nigra. Program No. 918.5.2005. Abstract Viewer/Itinerary Planner. 2005;Available at: http://sfn.scholarone.com/itin2005/main.html? new_page_id=126&abstract_id=3411&p_num=918.5&is_tech=0. Accessed April 27, 2006.
  • 98.Stanimirovic DB, Wong J, Ball R, Durkin JP. Free radical-induced endothelial membrane dysfunction at the site of blood-brain barrier: relationship between lipid peroxidation, Na,K-ATPase activity, and 51 Cr release. Neurochem Res. 1995;20:1417–1427. doi: 10.1007/BF00970589. [DOI] [PubMed] [Google Scholar]
  • 99.Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173–185. doi: 10.1124/pr.57.2.4. [DOI] [PubMed] [Google Scholar]
  • 100.Bankson MG, Yamamoto BK. MDMA Causes Long-term Increases in Blood Brain Barrier Permeability. Program No. 190.4.2005 Abstract Viewer/Itinerary Planner 2005; Available at: http://sfn. scholarone.com/itin2005/main.html? new_page_id=126&abstract_id=15187&p_num=190.4&is_tech=0 Accessed April 27, 2006.

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES